EVEREST MED (01952) Company Profile - Company Info, Industry & Management

返回 Overview News Financials Shareholders Profile IPO ›

Industry

Innovative Drugs & Biologics 0.02%

124 stocks in this industry

3 >7%

3 5~7%

10 3~5%

36 0~3%

15 0%

38 0~3%

13 3~5%

1 5~7%

5 >7%

Down 52 Up 57

Industry RankingsValue (HKD)Rank

Revenue (Last FY)2.00B41/112

Net Profit (Last FY)-349.18M98/125

ROE (Last FY)-5.61%60/117

Change is the 2026-10-09 close against the previous close; the industry change is the equal-weighted average of its stocks. Sub-industry classification is maintained by cibo. Last FY is each company's latest annual report. Net profit is profit attributable to owners of the parent; ROE = net profit / closing equity attributable to owners. Non-HKD statements are converted at ECB reference rates.

Management

NamePosition

Yifang Wu Executive Director

Yongqing Luo Executive Director

Ian Ying Woo Executive Director

Wei Fu Non-Executive Director

Xin Sun Non-Executive Director

Yue Wang Non-Executive Director

Hoi Yam Chui Independent Non-Executive Director

Yifan Li Independent Non-Executive Director

Shidong Jiang Independent Non-Executive Director

Board list from the HKEXnews "List of Directors and their Role and Function", as of 2026-08-14.

About this page

This page shows EVEREST MED (01952) company information, related securities, the price change distribution and in-industry rankings within its sub-industry, and the board of directors. Quotes come from HKEX Daily Quotations, financial metrics from each company's latest annual report, and the director list from HKEXnews.

EVEREST MED 01952

Company Information

Industry

Management

EVEREST MED 01952·

Company Information

Industry

Management

EVEREST MED 01952